Primary-source record

MaterialTopline results

Harmony Biosciences Reports Positive MAD Data for BP-205 Orexin Agonist

Harmony announced preliminary results from the Phase 1 multiple-ascending dose study of BP-205 showing favorable safety, tolerability, and PK profile with once-daily dosing. No liver, visual, or serious adverse events were reported. Phase 1b data in sleep-deprived volunteers remains on track for Q1 2027 readout.

Key facts

Filed
Nov 4, 2026, 01:00 PM
Event
Topline results
Direction
Neutral
Asset
BP-205
Source
SEC 8-K
Confidence
Sourced
t max
60 minutes
half life
29 hours
urinary AE
<20% at 1-3mg
headache AE
25%
insomnia AE
<20%

Source excerpt

EX-99.1 2 hrmy-ex99d1.htm EX-99.1 ‌ Exhibit 99.1 Harmony Biosciences Reports Q3 Financial Results On Track to Achieve More Than $1 Billion WAKIX Net Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile ​ WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B ​ Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending Dose Study Reinforces Favorable Safety, Tolerability and Pharmacokinetic Profile Observed in Single-Ascending Dose Study ​ Results from Phase 1b Study in Sleep-Deprived Healthy Volunteers for BP-205 Remain on Track for Q1 2027; Phase 2 Studies in Multiple CNS Indications Expected to Initiate by Mid-2027 ​ Pitolisant GR NDA Under FDA Review, PDUFA Date April 1, 2027; Pitolisant HD Phase 3 Topline Data in 2027, Target PDUFA Date in 2028 ​ Multi-Layered IP Strategy Across Active Legal Proceedings Reinforces Confidence in WAKIX Exclusivity to March 2030 ​ Peter Anastasiou to Succeed Jeffrey Dayno, MD, as President and Chief Executive Officer Effective January 1, 2027 ​ Conference Call and Webcast Today at 8:30 a.m. ET ​ PLYMOUTH MEETING, Pa., November 4, 2026 /Globe Newswire/ -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today reported third quarter 2026 financial results and preliminary data from its multiple-ascending dose (MAD) clinical study for its potential best-in-clas

SEC 8-K

More on this asset

Oct 13, 2026
12:00 PM
HRMYHarmony Biosciences

Harmony Biosciences Reiterates BP-205 MAD Study Data in Q4 2026

Trial registry changeSEC 8-K
Harmony Biosciences Reports Positive MAD Data for BP-205 Orexin Agonist | SimianX AI